Doxorubicin-poly (ethylene Glycol)-alendronate Self-assembled Micelles for Targeted Therapy of Bone Metastatic Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2015 Oct 1

PMID 26419507

Citations 27

Authors

Wei-Liang Ye

Yi-Pu Zhao

Huai-Qiu Li

Ren Na

Fei Li

Qi-Bing Mei

Ming-Gao Zhao

Si-Yuan Zhou

Affiliations

Soon will be listed here.

Abstract

In order to increase the therapeutic effect of doxorubicin (DOX) on bone metastases, a multifunctional micelle was developed by combining pH-sensitive characteristics with bone active targeting capacity. The DOX loaded micelle was self-assembled by using doxorubicin-poly (ethylene glycol)-alendronate (DOX-hyd-PEG-ALN) as an amphiphilic material. The size and drug loading of DOX loaded DOX-hyd-PEG-ALN micelle was 114 nm and 24.3%. In pH 5.0 phosphate buffer solution (PBS), the micelle released DOX significantly faster than in pH 7.4 PBS. In addition, with the increase of incubation time, more red DOX fluorescence was observed in tumor cells and trafficked from cytoplasm to nucleus. The IC50 of DOX loaded DOX-hyd-PEG-ALN micelle on A549 cells was obviously lower than that of free DOX in 48 h. Furthermore, the in vivo image experimental results indicated that a larger amount of DOX was accumulated in the bone metastatic tumor tissue after DOX loaded DOX-hyd-PEG-ALN micelle was intravenously administered, which was confirmed by histological analysis. Finally, DOX loaded DOX-hyd-PEG-ALN micelle effectively delayed the tumor growth, decreased the bone loss and reduced the cardiac toxicity in tumor-bearing nude mice as compared with free DOX. In conclusion, DOX loaded DOX-hyd-PEG-ALN micelle had potential in treating bone metastatic tumor.

Citing Articles

Nanotheranostics in Breast Cancer Bone Metastasis: Advanced Research Progress and Future Perspectives.

Miao L, Zhu Y, Chang H, Zhang X Pharmaceutics. 2025; 16(12.

PMID: 39771471 PMC: 11676679. DOI: 10.3390/pharmaceutics16121491.

Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B.

Basar E, Mead H, Shum B, Rauter I, Ay C, Skaletz-Rorowski A Pharmaceutics. 2024; 16(9).

PMID: 39339243 PMC: 11435036. DOI: 10.3390/pharmaceutics16091207.

Dual ligand-targeted Pluronic P123 polymeric micelles enhance the therapeutic effect of breast cancer with bone metastases.

Gao H, Zhang J, Kleijn T, Wu Z, Liu B, Ma Y Oncol Res. 2024; 32(4):769-784.

PMID: 38560569 PMC: 10972726. DOI: 10.32604/or.2023.044276.

Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges.

Yu X, Zhu L Int J Nanomedicine. 2024; 19:1867-1886.

PMID: 38414525 PMC: 10898486. DOI: 10.2147/IJN.S442768.

Facile synthesis of layered double hydroxide nanosheets assembled porous structures for efficient drug delivery.

Wang X, Lu H, Liao B, Li G, Chen L RSC Adv. 2023; 13(18):12059-12064.

PMID: 37082376 PMC: 10111147. DOI: 10.1039/d3ra01000g.

References

Salerno M, Cenni E, Fotia C, Avnet S, Granchi D, Castelli F . Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr Cancer Drug Targets. 2010; 10(7):649-59. DOI: 10.2174/156800910793605767. View

Peek L, Roberts L, Berkland C . Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins. Langmuir. 2008; 24(17):9775-83. PMC: 3729861. DOI: 10.1021/la8012014. View

Swami A, Reagan M, Basto P, Mishima Y, Kamaly N, Glavey S . Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A. 2014; 111(28):10287-92. PMC: 4104924. DOI: 10.1073/pnas.1401337111. View

Hengst V, Oussoren C, Kissel T, Storm G . Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm. 2006; 331(2):224-7. DOI: 10.1016/j.ijpharm.2006.11.024. View

Wang D, Sima M, Mosley R, Davda J, Tietze N, Miller S . Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm. 2006; 3(6):717-25. PMC: 2504859. DOI: 10.1021/mp0600539. View

Ye W, Du J, Zhang B, Na R, Song Y, Mei Q . Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles. PLoS One. 2014; 9(5):e97358. PMC: 4020841. DOI: 10.1371/journal.pone.0097358. View

Mai Y, Eisenberg A . Self-assembly of block copolymers. Chem Soc Rev. 2012; 41(18):5969-85. DOI: 10.1039/c2cs35115c. View

Deng X, Xiong L, Lin L, Xiong G, Miao X . Photosan-II loaded hollow silica nanoparticles: preparation and its effect in killing for QBC939 cells. Photodiagnosis Photodyn Ther. 2013; 10(4):460-9. DOI: 10.1016/j.pdpdt.2013.04.002. View

Kulkarni S, Feng S . Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res. 2013; 30(10):2512-22. DOI: 10.1007/s11095-012-0958-3. View

10.

Clementi C, Miller K, Mero A, Satchi-Fainaro R, Pasut G . Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharm. 2011; 8(4):1063-72. DOI: 10.1021/mp2001445. View

11.

Miller K, Erez R, Segal E, Shabat D, Satchi-Fainaro R . Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl. 2009; 48(16):2949-54. DOI: 10.1002/anie.200805133. View

12.

Duan X, Li Y . Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small. 2012; 9(9-10):1521-32. DOI: 10.1002/smll.201201390. View

13.

Iyer A, Khaled G, Fang J, Maeda H . Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006; 11(17-18):812-8. DOI: 10.1016/j.drudis.2006.07.005. View

14.

Lalatsa A, Schatzlein A, Mazza M, Le T, Uchegbu I . Amphiphilic poly(L-amino acids) - new materials for drug delivery. J Control Release. 2012; 161(2):523-36. DOI: 10.1016/j.jconrel.2012.04.046. View

15.

Andersson L, Davies J, Duncan R, Ferruti P, Ford J, Kneller S . Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. Biomacromolecules. 2005; 6(2):914-26. DOI: 10.1021/bm049381p. View

16.

Capeloa T, Caramelo F, Fontes-Ribeiro C, Gomes C, Silva A . Role of methamphetamine on glioblastoma cytotoxicity induced by doxorubicin and methotrexate. Neurotox Res. 2014; 26(3):216-27. DOI: 10.1007/s12640-014-9464-1. View

17.

Lin J . Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996; 18(2):75-85. DOI: 10.1016/8756-3282(95)00445-9. View

18.

Lin D, Li G, Qin L, Wen Z, Wang J, Sun X . Preparation, characterization and uptake of PEG-coated, muco-inert nanoparticles in HGC-27 cells, a mucin-producing, gastric-cancer cell line. J Biomed Nanotechnol. 2013; 9(12):2017-23. DOI: 10.1166/jbn.2013.1708. View

19.

Molavi O, Mahmud A, Hamdy S, Hung R, Lai R, Samuel J . Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy. Mol Pharm. 2009; 7(2):364-74. DOI: 10.1021/mp900145g. View

20.

Dobrovolskaia M, Aggarwal P, Hall J, McNeil S . Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008; 5(4):487-95. PMC: 2613572. DOI: 10.1021/mp800032f. View